Professor Ost leads his team focusing on urothelial cancers with a strong research focus on prostate cancer. In this field they have followed and implemented new technologies such as IMRT, SBRT, VMAT as well as new systemic treatments such as abiraterone, enzalutamide…. Another important focus is the implementation of new diagnostic tools in the re-staging of prostate cancer and implementation of metastasis-directed therapy for prostate cancer with limited metastases (oligometastases).

A recent interest in this field is the development of prognostic or predictive circulating biomarkers panels for which collaboration with several other departments has been established inside and outside Ugent.